Compare Amgen, Inc. (AMGN) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Nvidia Corp — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Nvidia Corp trades at $207.97 (market cap $5.11T). The key difference: Nvidia Corp is far larger — about 26.1× Amgen, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | NVDA | |
|---|---|---|
Market Cap | $196.12B | $5.11T |
Sector | Health | Technology |
52-Week High | $388.16 | $235.75 |
52-Week Low | $271.18 | $164.07 |
Enterprise Value | $241.41B | $5.04T |
Dividend Yield | 2.77% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
NVIDIA (NVDA) trades at $210.96, up 4.07% today, with a bullish technical signal from moving averages. The company reported robust fundamentals, including a 130.5B revenue in 2025 and a net income margin of 62.97%. Recent earnings beats and strong cash flow from operations of $64.09B highlight operational strength. Analyst consensus is strongly bullish with a $324.95 price target, though the stock faces risks from competition and market volatility.
Outlook remains positive driven by AI chip demand, with revenue projected to reach $253.5B in 2026. However, investors should weigh high valuation multiples like a P/E of 32.31 and competitive pressures. The stock offers significant upside per analyst targets but requires monitoring of execution risks and macroeconomic factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
